Latest News

The resubmission is considered a Class 1 submission and has a current PDUFA target action date of July 29, 2026.

Belite Bio has completed its rolling NDA submission to the FDA for tinlarebant, a potential first approved treatment for Stargardt disease type 1.

Optical coherence tomography angiography found distinctive microvascular signatures in the retinal layers associated with various stages of decline in cognition.

A midyear recap of the cataract-related news Ophthalmology Times has covered in 2026

Host Deborah Ristvedt, DO, welcomes Vance Thompson, MD, to discuss how prioritizing people has shaped the culture and growth of Vance Thompson Vision.

Step-by-step prompting boosts multimodal AI accuracy on bilingual ophthalmology vignettes with images—but weak subspecialty and image-reading skills remain.

A case report describes image-guided surgical excision combined with adjunctive cryotherapy and a single anterior chamber methotrexate injection, with no recurrence at 10 months.

In part 2 of a 2-part Q&A, John Berdahl, MD, weighs in on AI-driven IOL power calculation in challenging eyes, best practices for reducing posterior capsule opacification, and how surgical mission work abroad has shaped his approach in the OR.

Three-year gene therapy data, an FDA reversal in wet AMD, light-powered dry eye treatment, a new macular supplement, and progress in childhood glaucoma—our review breaks down the 5 May 2026 stories that matter.

The FDA approved the TECNIS PureSee IOL (model ZEN00V) on March 12, 2026.

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

Alkeus Pharmaceuticals has dosed the first participant in the phase 3 NORTHSTAR trial of oral gildeuretinol for Stargardt disease, a condition with no approved treatments.

Finding satisfaction in ocular research—considerations about AI and enhanced datasets.